CMMB - Chemomab Therapeutics Ltd Latest Stock News & Market Updates

robot
Abstract generation in progress

This page provides news and market updates for Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotechnology company developing nebokitug for fibro-inflammatory diseases, particularly primary sclerosing cholangitis (PSC). It highlights the company’s clinical trial results, regulatory milestones, financial updates, and investor outreach activities. Recent news focuses on positive Phase 2 SPRING trial data for nebokitug in PSC and progress towards Phase 3 trials and regulatory approval.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)